^
    1year
    CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. (PubMed, Leukemia)
    One patient had progression free survival of >3 years. With manageable toxicity profile, GC027 demonstrated superior clinical efficacy to standard chemotherapy regimens in (R/R) T cell malignancies.
    Preclinical • Journal
    |
    CD7 (CD7 Molecule)
    |
    GC027
    3years
    Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies (ASH 2021)
    It demonstrated robust anti-tumor efficacy and promising potentials to suppress HvG. This report presents an example that the dual CAR design of GC502 may serve as a novel “off-the-shelf” CAR-T technology.
    Preclinical • CAR T-Cell Therapy • IO biomarker
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • CD7 (CD7 Molecule)
    |
    CD19 expression
    |
    GC027 • GC502
    over3years
    Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Xinqiao Hospital of Chongqing | Not yet recruiting --> Recruiting | Trial completion date: Apr 2022 --> Jun 2023 | Trial primary completion date: Apr 2021 --> Jun 2022
    Clinical • Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    melphalan • fludarabine IV • GC027 • cyclophosphamide intravenous
    almost4years
    [VIRTUAL] Updates on clinical safety and efficacy result of GC027, the first-in-human, “Off-the-Shelf” CD7 CAR-T stand-alone therapy for adult patients with relapsed/refractory T-cell lymphoblastic leukemia (r/r T-ALL) (AACR 2021)
    The allogeneic off-the-shelf TruUCAR™ CAR-T GC027 shows promising efficacy as standalone therapy in heavily pretreated R/R T-ALL pts with a manageable safety profile. A single infusion of GC027 was able to induce deep, durable responses, with the longest duration of response (MRD-CR) 18 months post treatment still ongoing without any additional therapy during remission. GC027 warrants further evaluation in larger clinical studies.
    Clinical • P1 data • Late-breaking abstract
    |
    CD7 (CD7 Molecule)
    |
    GC027
    over4years
    [VIRTUAL] Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) (AACR-I 2020)
    With a single infusion of GC027, 80% of the patients had robust CAR-T cell expansion and achieved persistent MRD- CR without using any biologics as part of the preconditioning therapy or bridging to HSCT. As the first-in-human, universal CAR-T therapy for adult r/r T-ALL, GC027 has demonstrated superior clinical efficacy and induced deep response in patients with acceptable safety profile. The trial enrollment is ongoing and updated data will be presented at the meeting.
    Clinical • P1 data
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6)
    |
    GC027